论文部分内容阅读
ＡＭ２８５在临床试验中ＡＭ２８５是瑞普里根（Ｒｅｐｌｌｇｅｎ）公司开发的肌酸激酶调节剂，正在进行用于癌症治疗的临床试验。它还具有抗病毒作用，公司称１９９４年下半年将进行临床评估。在４月份的ＡｎｔｉｖｉｒａｌＲｅｓｅａｒｃｈ杂志上美国研究者报道体外和动...
AM285 In clinical trials AM285 is a creatine kinase modulator developed by Repllgen and is undergoing clinical trials for the treatment of cancer. It also has an antiviral effect and the company said it will conduct a clinical evaluation in the second half of 1994. In the April issue of AntiviralResearch, US researchers reported in vitro and in ...